Top

Published in:

01-11-2020 | Heart Failure

Long non-coding RNAs in cardiac hypertrophy

Authors: Jinghui Sun, Chenglong Wang

Published in: Heart Failure Reviews | Issue 6/2020

Abstract

Cardiac hypertrophy (CH) is generally considered adaptive responses that may occur after myocardial infarction, pressure overload, volume overload, inflammatory heart muscle disease, or idiopathic dilated cardiomyopathy, whereas long-term stimulation eventually leads to heart failure (HF). However, the current molecular mechanisms involved in CH are unclear. Recently, increasing evidences reveal that long non-coding RNAs (lncRNAs) play vital roles in CH. Different lncRNAs can promote or inhibit the pathological process of CH by different mechanisms, while the regulation of lncRNAs expression can improve CH. Thus, CH-related lncRNAs may become a novel field of research on CH.

Balakumar P, Jagadeesh G (2010) Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared? Pharmacol Res 62:365–383PubMed

Frey N, Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45–79PubMed

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DJ, Drazner MH et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:1810–1852PubMed

Lyon RC, Zanella F, Omens JH, Sheikh F (2015) Mechanotransduction in cardiac hypertrophy and failure. Circ Res 116:1462–1476PubMedPubMedCentral

Dunham IKAAS (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57–74

Da SL, Baldassarre A, Masotti A (2012) Bioinformatics tools and novel challenges in long non-coding RNAs (lncRNAs) functional analysis. Int J Mol Sci 13:97–114

Shang D, Yang H, Xu Y, Yao Q, Zhou W, Shi X, Han J, Su F, Su B, Zhang C, Li C, Li X (2015) A global view of network of lncRNAs and their binding proteins. Mol BioSyst 11:656–663PubMed

Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, Lawrence JB (2009) An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. Mol Cell 33:717–726PubMedPubMedCentral

Gong C, Maquat LE (2011) lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. Nature 470:284–288PubMedPubMedCentral

10.

Ginger MR, Shore AN, Contreras A, Rijnkels M, Miller J, Gonzalez-Rimbau MF, Rosen JM (2006) A noncoding RNA is a potential marker of cell fate during mammary gland development. Proc Natl Acad Sci U S A 103:5781–5786PubMedPubMedCentral

11.

Kanduri C (2011) Kcnq1ot1: a chromatin regulatory RNA. Semin Cell Dev Biol 22:343–350PubMed

12.

Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, Tramontano A, Bozzoni I (2011) A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147:358–369PubMedPubMedCentral

13.

Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10:155–159PubMed

14.

Li X, Zhang L, Liang J (2016) Unraveling the expression profiles of long noncoding RNAs in rat cardiac hypertrophy and functions of lncRNA BC088254 in cardiac hypertrophy induced by transverse aortic constriction. Cardiology 134:84–98PubMed

15.

Sun L, Zhang Y, Zhang Y, Gu Y, Xuan L, Liu S et al (2014) Expression profile of long non-coding RNAs in a mouse model of cardiac hypertrophy. Int J Cardiol 177:73–75PubMed

16.

Zhang Y, Su L, Zhang K (2016) Transcriptional Effects of E3 Ligase Nrdp1 on Hypertrophy in neonatal rat cardiomyocytes by microarray and integrated gene network analysis. Cardiology 135:203–215PubMed

17.

Song C, Zhang J, Liu Y, Pan H, Qi HP, Cao YG et al (2016) Construction and analysis of cardiac hypertrophy-associated lncRNA-mRNA network based on competitive endogenous RNA reveal functional lncRNAs in cardiac hypertrophy. Oncotarget 7:10827–10840PubMedPubMedCentral

18.

Wang K, Liu F, Zhou LY, Long B, Yuan SM, Wang Y, Liu CY, Sun T, Zhang XJ, Li PF (2014) The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 114:1377–1388PubMed

19.

Ha T, Hua F, Li Y, Ma J, Gao X, Kelley J et al (2006) Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 290:H985–H994PubMed

20.

Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schürmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP, Schroen B (2013) Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation 128:1420–1432PubMed

21.

Wo Y, Guo J, Li P, Yang H, Wo J (2018) Long non-coding RNA CHRF facilitates cardiac hypertrophy through regulating Akt3 via miR-93. Cardiovasc Pathol 35:29–36PubMed

22.

Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600PubMed

23.

Dorn GN, Force T (2005) Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527–537PubMedPubMedCentral

24.

Taniyama Y, Ito M, Sato K, Kuester C, Veit K, Tremp G, Liao R, Colucci WS, Ivashchenko Y, Walsh K, Shiojima I (2005) Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy. J Mol Cell Cardiol 38:375–385PubMed

25.

Yu X, Zou T, Zou L, Jin J, Xiao F, Yang J (2017) Plasma long noncoding RNA urothelial carcinoma associated 1 predicts poor prognosis in chronic heart failure patients. Med Sci Monit 23:2226–2231PubMedPubMedCentral

26.

Zhou G, Li C, Feng J, Zhang J, Fang Y (2018) lncRNA UCA1 is a novel regulator in cardiomyocyte hypertrophy through targeting the miR-184/HOXA9 axis. Cardiorenal Med 8:130–139PubMedPubMedCentral

27.

Pirro M, Schillaci G, Menecali C, Bagaglia F, Paltriccia R, Vaudo G, Mannarino MR, Mannarino E (2007) Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. J Hypertens 25:2093–2099PubMed

28.

Wen ZQ, Li SH, Shui X, Tang LL, Zheng JR, Chen L (2019) LncRNA PEG10 aggravates cardiac hypertrophy through regulating HOXA9. Eur Rev Med Pharmacol Sci 23:281–286PubMed

29.

Jiang F, Zhou X, Huang J (2016) Long non-coding RNA-ROR mediates the reprogramming in cardiac hypertrophy. PLoS One 11:e152767

30.

Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P et al (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613–618PubMed

31.

Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M et al (2016) Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med 8:322r–326r

32.

McEwan DG, Popovic D, Gubas A, Terawaki S, Suzuki H, Stadel D, Coxon FP, Miranda de Stegmann D, Bhogaraju S, Maddi K, Kirchof A, Gatti E, Helfrich MH, Wakatsuki S, Behrends C, Pierre P, Dikic I (2015) PLEKHM1 regulates autophagosome-lysosome fusion through HOPS complex and LC3/GABARAP proteins. Mol Cell 57:39–54PubMed

33.

Taneike M, Yamaguchi O, Nakai A, Hikoso S, Takeda T, Mizote I, Oka T, Tamai T, Oyabu J, Murakawa T, Nishida K, Shimizu T, Hori M, Komuro I, Takuji Shirasawa TS, Mizushima N, Otsu K (2010) Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy 6:600–606PubMed

34.

Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S et al (2012) The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 3:1078PubMed

35.

Wang Y, Cao R, Yang W, Qi B (2019) SP1-SYNE1-AS1-miR-525-5p feedback loop regulates Ang-II-induced cardiac hypertrophy. J Cell Physiol 234:14319–14329PubMed

36.

Dong ZX, Wan L, Wang RJ, Shi YQ, Liu GZ, Zheng SJ, Hou HL, Han W, Hai X (2017) (-)-Epicatechin Suppresses angiotensin II-induced cardiac hypertrophy via the activation of the SP1/SIRT1 signaling pathway. Cell Physiol Biochem 41:2004–2015PubMed

37.

Hu X, Li T, Zhang C, Liu Y, Xu M, Wang W, Jia Z, Ma K, Zhang Y, Zhou C (2011) GATA4 regulates ANF expression synergistically with Sp1 in a cardiac hypertrophy model. J Cell Mol Med 15:1865–1877PubMedPubMedCentral

38.

Chen X, Zeng K, Xu M, Hu X, Liu X, Xu T et al (2018) SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis. Cell Death Dis 9:982PubMedPubMedCentral

39.

Dong H, Wang W, Mo S, Chen R, Zou K, Han J et al (2018) SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88. J Exp Clin Cancer Res 37:202PubMedPubMedCentral

40.

Zhang J, Liang Y, Huang X, Guo X, Liu Y, Zhong J et al (2019) STAT3-induced upregulation of lncRNA MEG3 regulates the growth of cardiac hypertrophy through miR-361-5p/HDAC9 axis. Sci Rep 9:460PubMedPubMedCentral

41.

Zhang Z, Zhang L, Zhou Y, Li L, Zhao J, Qin W et al (2019) Increase in HDAC9 suppresses myoblast differentiation via epigenetic regulation of autophagy in hypoxia. Cell Death Dis 10:552PubMedPubMedCentral

42.

Lino CC, Kessinger CW, Cheng Y, MacDonald C, MacGillivray T, Ghoshhajra B et al (2018) An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm. Nat Commun 9:1009

43.

Wang Z, Zhang XJ, Ji YX, Zhang P, Deng KQ, Gong J, Ren S, Wang X, Chen I, Wang H, Gao C, Yokota T, Ang YS, Li S, Cass A, Vondriska TM, Li G, Deb A, Srivastava D, Yang HT, Xiao X, Li H, Wang Y (2016) The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med 22:1131–1139PubMedPubMedCentral

44.

Joh RI, Palmieri CM, Hill IT, Motamedi M (2014) Regulation of histone methylation by noncoding RNAs. Biochim Biophys Acta 1839:1385–1394PubMedPubMedCentral

45.

Gould A (1997) Functions of mammalian Polycomb group and trithorax group related genes. Curr Opin Genet Dev 7:488–494PubMed

46.

Zhu XH, Yuan YX, Rao SL, Wang P (2016) LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR-150. Eur Rev Med Pharmacol Sci 20:3653–3660PubMed

47.

Liu W, Liu Y, Zhang Y, Zhu X, Zhang R, Guan L, Tang Q, Jiang H, Huang C, Huang H (2015) MicroRNA-150 Protects against pressure overload-induced cardiac hypertrophy. J Cell Biochem 116:2166–2176PubMed

48.

Deng P, Chen L, Liu Z, Ye P, Wang S, Wu J, Yao Y, Sun Y, Huang X, Ren L, Zhang A, Wang K, Wu C, Yue Z, Xu X, Chen M (2016) MicroRNA-150 inhibits the activation of cardiac fibroblasts by regulating c-Myb. Cell Physiol Biochem 38:2103–2122PubMed

49.

Yan B, Yao J, Liu JY, Li XM, Wang XQ, Li YJ, Tao ZF, Song YC, Chen Q, Jiang Q (2015) lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res 116:1143–1156PubMed

50.

Shen Y, Dong LF, Zhou RM, Yao J, Song YC, Yang H et al (2016) Role of long non-coding RNA MIAT in proliferation, apoptosis and migration of lens epithelial cells: a clinical and in vitro study. J Cell Mol Med 20:537–548PubMedPubMedCentral

51.

Li Y, Wang J, Sun L, Zhu S (2018) LncRNA myocardial infarction-associated transcript (MIAT) contributed to cardiac hypertrophy by regulating TLR4 via miR-93. Eur J Pharmacol 818:508–517PubMed

52.

Ehrentraut H, Weber C, Ehrentraut S, Schwederski M, Boehm O, Knuefermann P et al (2011) The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. Eur J Heart Fail 13:602–610PubMed

53.

Katare PB, Bagul PK, Dinda AK, Banerjee SK (2017) Toll-Like receptor 4 inhibition improves oxidative stress and mitochondrial health in isoproterenol-induced cardiac hypertrophy in rats. Front Immunol 8:719PubMedPubMedCentral

54.

Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, William Browder I, Kao RL, Li C (2005) Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 68:224–234PubMed

55.

Li C, Zhou G, Feng J, Zhang J, Hou L, Cheng Z (2018) Upregulation of lncRNA VDR/CASC15 induced by facilitates cardiac hypertrophy through modulating miR-432-5p/TLR4 axis. Biochem Biophys Res Commun 503:2407–2414PubMed

56.

Davis-Dusenbery BN, Wu C, Hata A (2011) Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol 31:2370–2377PubMedPubMedCentral

57.

Jin L, Lin X, Yang L, Fan X, Wang W, Li S, Li J, Liu X, Bao M, Cui X, Yang J, Cui Q, Geng B, Cai J (2018) AK098656, a novel vascular smooth muscle cell-dominant long noncoding RNA, promotes hypertension. Hypertension 71:262–272PubMed

58.

Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 146:353–358PubMedPubMedCentral

59.

Lai Y, He S, Ma L, Lin H, Ren B, Ma J, Zhu X, Zhuang S (2017) HOTAIR functions as a competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy. Mol Cell Biochem 432:179–187PubMed

60.

Oudit GY, Penninger JM (2009) Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82:250–260PubMed

61.

Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos A, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM (2002) Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110:737–749PubMed

62.

Zhang T, Kohlhaas M, Backs J, Mishra S, Phillips W, Dybkova N et al (2007) CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J Biol Chem 282:35078–35087PubMed

63.

Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, Richardson JA, Hill JA, Katus HA, Bassel-Duby R, Maier LS, Olson EN (2009) The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A 106:2342–2347PubMedPubMedCentral

64.

Shao M, Chen G, Lv F, Liu Y, Tian H, Tao R, Jiang R, Zhang W, Zhuo C (2017) LncRNA TINCR attenuates cardiac hypertrophy by epigenetically silencing CaMKII. Oncotarget 8:47565–47573PubMedPubMedCentral

65.

Yuan Y, Wang J, Chen Q, Wu Q, Deng W, Zhou H, Shen D (2019) Long non-coding RNA cytoskeleton regulator RNA (CYTOR) modulates pathological cardiac hypertrophy through miR-155-mediated IKKi signaling. Biochim Biophys Acta Mol basis Dis 1865:1421–1427PubMed

66.

Dai J, Shen DF, Bian ZY, Zhou H, Gan HW, Zong J et al (2013) IKKi deficiency promotes pressure overload-induced cardiac hypertrophy and fibrosis. PLoS One 8:e53412PubMedPubMedCentral

67.

Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng R, Wang Y, Huang J, Xu M, Yan J, Yu J (2014) lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. FEBS J 281:3766–3775PubMed

68.

Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, Reik W (2012) The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol 14:659–665PubMedPubMedCentral

69.

Gao WL, Liu M, Yang Y, Yang H, Liao Q, Bai Y, Li YX, Li D, Peng C, Wang YL (2012) The imprinted H19 gene regulates human placental trophoblast cell proliferation via encoding miR-675 that targets Nodal Modulator 1 (NOMO1). RNA Biol 9:1002–1010PubMed

70.

Liu L, An X, Li Z, Song Y, Li L, Zuo S, Liu N, Yang G, Wang H, Cheng X, Zhang Y, Yang X, Wang J (2016) The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy. Cardiovasc Res 111:56–65PubMed

71.

Anderson ME, Brown JH, Bers DM (2011) CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 51:468–473PubMedPubMedCentral

72.

Lv L, Li T, Li X, Xu C, Liu Q, Jiang H, Li Y, Liu Y, Yan H, Huang Q, Zhou Y, Zhang M, Shan H, Liang H (2018) The lncRNA Plscr4 controls cardiac hypertrophy by regulating miR-214. Mol Ther Nucleic Acids 10:387–397PubMed

73.

Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003) Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160:189–200PubMedPubMedCentral

74.

Guan X, Wang L, Liu Z, Guo X, Jiang Y, Lu Y, Peng Y, Liu T, Yang B, Shan H, Zhang Y, Xu C (2016) miR-106a promotes cardiac hypertrophy by targeting mitofusin 2. J Mol Cell Cardiol 99:207–217PubMed

75.

Yu H, Guo Y, Mi L, Wang X, Li L, Gao W (2011) Mitofusin 2 inhibits angiotensin II-induced myocardial hypertrophy. J Cardiovasc Pharmacol Ther 16:205–211PubMed

76.

Zhao Y, Ponnusamy M, Liu C, Tian J, Dong Y, Gao J, Wang C, Zhang Y, Zhang L, Wang K, Li P (2017) MiR-485-5p modulates mitochondrial fission through targeting mitochondrial anchored protein ligase in cardiac hypertrophy. Biochim Biophys Acta Mol basis Dis 1863:2871–2881PubMed

77.

Wang Z, Niu Q, Peng X, Li M, Liu K, Liu Y, Liu J, Jin F, Li X, Wei Y (2016) Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR. Int J Cardiol 214:348–357PubMed

78.

Chen Y, Liu X, Chen L, Chen W, Zhang Y, Chen J et al (2018) The long noncoding RNA XIST protects cardiomyocyte hypertrophy by targeting miR-330-3p. Biochem Biophys Res Commun 505:807–815PubMed

79.

Tsoporis JN, Mohammadzadeh F, Parker TG (2011) S100B: a multifunctional role in cardiovascular pathophysiology. Amino Acids 41:843–847PubMed

80.

Xiao L, Gu Y, Sun Y, Chen J, Wang X, Zhang Y, Gao L, Li L (2019) The long noncoding RNA XIST regulates cardiac hypertrophy by targeting miR-101. J Cell Physiol 234:13680–13692PubMed

81.

Wang JW, Fontes M, Wang X, Chong SY, Kessler EL, Zhang YN et al (2017) Leukocytic Toll-Like receptor 2 deficiency preserves cardiac function and reduces fibrosis in sustained pressure overload. Sci Rep 7:9193PubMedPubMedCentral

82.

Trentin-Sonoda M, Da SR, Kmit FV, Abrahao MV, Monnerat CG, Brasil GV et al (2015) Knockout of Toll-like receptors 2 and 4 prevents renal ischemia-reperfusion-induced cardiac hypertrophy in mice. PLoS One 10:e139350

83.

Luo Y, Xu Y, Liang C, Xing W, Zhang T (2018) The mechanism of myocardial hypertrophy regulated by the interaction between mhrt and myocardin. Cell Signal 43:11–20PubMed

84.

Cen B, Selvaraj A, Prywes R (2004) Myocardin/MKL family of SRF coactivators: key regulators of immediate early and muscle specific gene expression. J Cell Biochem 93:74–82PubMed

85.

Pipes GC, Creemers EE, Olson EN (2006) The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 20:1545–1556PubMed

86.

Parmacek MS (2007) Myocardin-related transcription factors: critical coactivators regulating cardiovascular development and adaptation. Circ Res 100:633–644PubMed

87.

Kontaraki JE, Parthenakis FI, Patrianakos AP, Karalis IK, Vardas PE (2007) Altered expression of early cardiac marker genes in circulating cells of patients with hypertrophic cardiomyopathy. Cardiovasc Pathol 16:329–335PubMed

88.

Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI, Vardas PE (2011) Early cardiac gene transcript levels in peripheral blood mononuclear cells in patients with untreated essential hypertension. J Hypertens 29:791–797PubMed

Title: Long non-coding RNAs in cardiac hypertrophy
Authors: Jinghui Sun
Chenglong Wang
Publication date: 01-11-2020
Publisher: Springer US
Keyword: Heart Failure
Published in: Heart Failure Reviews / Issue 6/2020
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-019-09882-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Long non-coding RNAs in cardiac hypertrophy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Acutely decompensated versus acute heart failure: two different entities

Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis

“The heart supporters”: systematic review for ventricle assist devices in congenital heart surgery

A miRNA’s insight into the regenerating heart: a concise descriptive analysis

Quality of life of chronic heart failure patients: a systematic review and meta-analysis

A manifesto of collaborative longitudinal cardiovascular care in heart failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page